Drugs /

dky709

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for dky709

Dky709 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dky709, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for dky709 clinical trials.

Breast carcinoma, colorectal carcinoma, and melanoma are the most common diseases being investigated in dky709 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dky709
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dky709 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.